期刊文献+

对中国医药市场监管体系建设的构想 被引量:5

Conception of supervision system of Chinese pharmaceutical market
下载PDF
导出
摘要 面对突出的药品安全问题,只有不断建立和完善医药监管的体制、机制、法制和信用体系等方面,才能促进规范有序的市场环境形成。监管机构的设置关系到整个药品安全监管体系的运行,要根据我国药监的情况确定适宜的方式。构成一个药品安全监管体系运行系统的因素包括:监管环境、监管主体、监管技术、监管制度等方面,各组成要素互相影响,相互作用。目前,我国药品监管法律的惩罚效力弱,对违法者起不到威慑的作用,因而建立和完善药品安全法律、法规、标准体系及其他制度是政府进行药品安全监管的保障。信用机制的治理从根本上说是一个长期的过程,在药监系统中倡导和弘扬诚实守信的良好风尚,对于整顿和规范药品市场秩序,维护人民群众的根本利益具有重要意义。 Facing the serious safe problems in Chinese pharmaceutical field, the only way to build a orderly market atmosphere is to establish and improve the pharmaceutical supervision system, mechanism, legal system, credit system, and so on. The establishment of supervision organization affects the running of the whole supervision system of Chinese pharmaceutical market, so we should make it suitable for the situation in China. The factors of building a supervision system of Chinese pharmaceutical market include supervision environment, supervision subject, supervision technology, supervision system and some other aspects. These factors influence and act each other. The present punishment of the law in medical supervision in China is weak, and it can not have the great function on the illegal events. So the government should build and promote the medical safety law, rules, criterion system and some other ones to make sure the running of medical safety supervision. It is a long way to manage the credit mechanism. The honest custom in pharmaceutical supervision is significant to make the pharmaceutical market to be in order and protect the people's benefits.
作者 高翔 陈荣秋
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第19期1547-1552,共6页 Chinese Journal of New Drugs
关键词 医药市场监管 监管体制 监管机制 监管法制 诚信体系 pharmaceutical market supervision supervision system supervision mechanism supervision legal system honest system
  • 相关文献

参考文献10

二级参考文献16

  • 1中国高技术产业发展年鉴2008.
  • 2陈建辉.研发新药还是无奈淡出[N].经济日报.2004
  • 3宗和.中国参与全球新药研发独具优势[N].医药经济报.2003(008)
  • 4本报记者 刘腾.调整药品研发政策,到时候了![N].财经时报.2003(018)
  • 5鲍仁.研发赢未来[N].医药经济报.2003(001)
  • 6.中国高技术产业统计年鉴[Z].中国统计出版社.
  • 7NSF.Science&EngineeringIndicators-2002[]..2002
  • 8OECD.ScienceTechnology andIndustryOutlook2002[]..2002
  • 9李玉辉,杜斌.重组国有医药商业的思考[J].商业研究,1999(1):21-22. 被引量:1
  • 10莫长塞,王英.虚拟化与中国医药产业研究开发策略[J].科技进步与对策,2000,17(1):61-63. 被引量:4

共引文献12

同被引文献31

  • 1张新平,郑明节.论我国药品监管体制的特点与创新[J].中国药房,2006,17(13):966-968. 被引量:6
  • 2ROBEZNIEKS A. FDA reform: is it enough? After a critical IOM report, agency moves to work harder on drug safety, but Congress presses ahead with its own changes [ J ]. Mod Healthc, 2007,37 (6):6-7, 1.
  • 3BERGER E. The future of drug safety: what the IOM report may mean to the emergency department[ J]. Ann Emerg Med,2007,49 (2) :193 - 195.
  • 4PSATY BM, BURKE SP. Protecting the health of the public-Institute of Medicine recommendations on drug safety [ J]. N Engl J Med, 2006,355(17) :1753 - 1755.
  • 5YOUNG D. IOM : congress must reform FDA to improve drug safety [J]. Am J Health Syst Pharm, 2006,63(21 ) :2032 -2034.
  • 6王俊豪.政府管制经济学导论[M].北京:商务印书馆,2004.
  • 7吴敬琏.中国增长模式抉择(增订版)[M].上海:上海远东出版社,2010,106.
  • 8韩雯雯.我国药品安全监管问题对策研究[D].吉林:吉林大学,2012.
  • 9冯继红.坚持政府主导,强化公益性质,全面推进县级公立医院综合改革[N].西部法制报,2011-11-01(5).
  • 10陈竺.把卫生新闻宣传工作摆到重要位置[EB/OL].(2011-11-16)[2012-09-06].http://www.med66.com/new/201209/pq201209061643.shtml.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部